Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Cross Cancer Institute, Edmonton, AB, Canada

Survival: 13.0 months
Toxicity Grade: 2
Country: Canada
City/State/Province: Edmonton, AB
Hospital: Cross Cancer Institute
Journal: Link
Date: 9/2005

Patients: This Phase II study involved 171 patients with advanced non-small-cell lung cancer who were randomly assigned into two groups. Group B had 83 patients (43 men, 40 women) with a median age of 59 years. All patients had either stable disease or a response to prior chemotherapy.

Treatment: The study focused on a biological therapeutic agent: BLP25. BLP25 is a vaccine that targets the MUC1 protein which is overexpressed in NSCLC tumor cells. Group B patients served as a control and did not receive BLP25.

Toxicity: No significant toxicities related to treatment were observed.

Results: For Group A, the median overall survival was 17.4 months. For Group B, the median overall survival was 13 months. However, the difference in survival between the groups was not statistically significant. The authors concluded, "The results reported here are promising and suggest that this minimally toxic vaccine might be valuable as maintenance therapy."

Support: Biomira and Merck supported this study, and several authors disclosed relationships with Biomira. Biomira develops and manufactures BLP25.

Correspondence: Charles Butts, MD

E-mail to a Friend Email Physician More Information